Randomized Phase II Study of Azacitidine Alone or in Combination With Lenalidomide or With Vorinostat in Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: North American Intergroup Study SWOG S1117.
about
Myelodysplastic and myeloproliferative neoplasms: updates on the overlap syndromes.A call for action: Increasing enrollment of untreated patients with higher-risk myelodysplastic syndromes in first-line clinical trials.Hypomethylating agent combination strategies in myelodysplastic syndromes: hopes and shortcomings.Hypomethylating agents (HMA) treatment for myelodysplastic syndromes: alternatives in the frontline and relapse settings.Phase 2, randomized, double-blind study of pracinostat in combination with azacitidine in patients with untreated, higher-risk myelodysplastic syndromes.Outcome of patients treated for myelodysplastic syndromes with 5q deletion after failure of lenalidomide therapy.A phase 1b/2b multicenter study of oral panobinostat plus azacitidine in adults with MDS, CMML or AML with ⩽30% blasts.Myelodysplastic syndromes: 2018 update on diagnosis, risk-stratification and management.Randomized study of continuous high-dose lenalidomide, sequential azacitidine and lenalidomide, or azacitidine in persons 65 years and over with newly-diagnosed acute myeloid leukemia.Therapy for Chronic Myelomonocytic Leukemia in a New Era."Epigenetic" modification as therapy for acute myeloid leukemia.Pevonedistat, a first-in-class NEDD8-activating enzyme (NAE) inhibitor, combined with azacitidine, in patients with AML.Combined drug therapeutic strategies for the effective treatment of Triple Negative Breast Cancer.Remarkably different results between two studies from North America on genomic mutations and sensitivity to DNA demethylating agents for myelodysplastic syndromes.Hypomethylating agents in myelodysplastic syndromes and population-level outcomes: a changing landscape or a small dent?Hypomethylating agents for treatment and prevention of relapse after allogeneic blood stem cell transplantation.More is less, less is more, or does it really matter? The curious case of impact of azacitidine administration schedules on outcomes in patients with myelodysplastic syndromes.Assessing treatment efficacy in the subset of responders in a randomized clinical trial.Comparable Outcomes of Patients Eligible versus Ineligible for SWOG Leukemia Studies.Counseling patients with higher-risk MDS regarding survival with azacitidine therapy: are we using realistic estimates?Beyond the Edge of Hypomethylating Agents: Novel Combination Strategies for Older Adults with Advanced MDS and AML.Molecular pathophysiology of the myelodysplastic syndromes: insights for targeted therapy
P2860
Q38644826-72C6A093-8937-44D3-A8DC-C7B105F26876Q38651923-ADE43F5F-DA03-4B05-A8D1-A1EA633F165DQ38961023-84C463C5-18CD-49F1-B10D-FEC0E6D1D51EQ39413114-D022BAF7-32C3-44D3-8790-FF2A49D8CD60Q40377702-EC125FDB-F066-4B5E-88C0-A4E8889EDFF5Q45923418-20C5F6E7-7142-4734-BA80-66641CAF9132Q47099325-4D8C4F1A-FDFC-4345-85F4-0C73E2482801Q47548041-A8810CB6-BEF9-4E40-B9C0-E2231017468AQ47665959-4962C000-B642-40E1-82EA-ABD5DFCAD2E4Q47853133-FFBD54DA-CDA7-4A91-80C4-D871F50D71ABQ48168123-FDE617F4-BC88-4042-B068-E54D492F5487Q48216923-69488D58-1414-461E-9336-74DF0FDCFCB2Q48551091-BA0FE6F9-7D60-44B2-9B8A-3C45C03EC7EAQ49592215-9A065379-D0F7-4DF3-B101-8616317CC56EQ49789581-F050170D-5AAD-4350-B7A4-8C2D21225CCDQ49976405-00B6877C-24F4-44F3-9290-C4DC9D1A2BC9Q50052465-F7977E13-7CFC-49F6-B952-A214825C9E49Q50700212-A46EF75B-A993-4630-83D2-D5B87289E790Q53832560-22F8FED1-1557-4DDB-A732-3D784521A8F3Q55035043-E7348F4C-9497-4C25-B465-805A1496DE29Q55515597-375E3360-84D9-4703-A5F7-2F39234749EAQ57795839-B00E9AAD-154C-4ECC-9DA8-9747BA632B9B
P2860
Randomized Phase II Study of Azacitidine Alone or in Combination With Lenalidomide or With Vorinostat in Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: North American Intergroup Study SWOG S1117.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh
2017年學術文章
@zh-hant
name
Randomized Phase II Study of A ...... n Intergroup Study SWOG S1117.
@en
Randomized Phase II Study of A ...... n Intergroup Study SWOG S1117.
@nl
type
label
Randomized Phase II Study of A ...... n Intergroup Study SWOG S1117.
@en
Randomized Phase II Study of A ...... n Intergroup Study SWOG S1117.
@nl
prefLabel
Randomized Phase II Study of A ...... n Intergroup Study SWOG S1117.
@en
Randomized Phase II Study of A ...... n Intergroup Study SWOG S1117.
@nl
P2093
P2860
P50
P356
P1476
Randomized Phase II Study of A ...... n Intergroup Study SWOG S1117.
@en
P2093
Alan F List
Alyssa H Cull
Anna Moseley
Aziz Nazha
Diane Roulston
Ehab Atallah
Elina K Cook
Eyal C Attar
Harry P Erba
Mario R Velasco
P2860
P304
P356
10.1200/JCO.2015.66.2510
P407
P577
2017-05-09T00:00:00Z